ArticleIn vitro cellular & developmental biology. Animal2019
C1QTNF6 as a novel biomarker regulates cellular behaviors in A549 cells and exacerbates the outcome of lung adenocarcinoma patients.
Article in In vitro cellular & developmental biology. Animal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Review
- Comprehensive characterization of pathogenic missense CTRP6 variants and their association with cancer.BMC cancer · 2025Article
- Article
- Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation.PloS one · 2023Article
- Mechanism of action of CTRP6 in the regulation of tumorigenesis in the digestive system.Oncology letters · 2022Review
- ANKRD49 promotes the invasion and metastasis of lung adenocarcinoma via a P38/ATF-2 signalling pathway.Journal of cellular and molecular medicine · 2022Article
- C1QTNF6 regulated by miR-29a-3p promotes proliferation and migration in stage I lung adenocarcinoma.BMC pulmonary medicine · 2022Article
- A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma.Journal of oncology · 2022Article
- C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis.Frontiers in pharmacology · 2022Article
- Advances in the functions of CTRP6 in the development and progression of the malignancy.Frontiers in genetics · 2022Review
- Role of the CTRP family in tumor development and progression.Oncology letters · 2021Review
- C1QTNF6 regulates cell proliferation and apoptosis of NSCLC in vitro and in vivo.Bioscience reports · 2021Article
- Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma.BioMed research international · 2020Article
- A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining.Oxidative medicine and cellular longevity · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C1q/tumor necrosis factor-related protein 6 (C1QTNF6) is a member of the CTRP family and implicated to cardiovascular diseases, inflammatory reaction, and adipogenesis. However, the function of C1QTNF6 in lung adenocarcinoma remains unknown. We downloaded the expression profiles of C1QTNF6 from TCGA database and Oncomine dataset in order to analyze the relationship between C1QTNF6 expression level and tumorigenesis by bioinformatics methods, such as chi-square test, Kaplan-Meier, and Cox regression analysis. In addition, we performed experiments to investigate the biological function of C1QTNF6 on cancer cells in vitro. The siRNA strategy was conducted to decrease the C1QTNF6 expression and then Cell Counting Kit-8 (CCK8) assay and wound-healing and transwell assays were to determine the proliferation, migration, and invasion. Western blot and qRT-PCR were used to confirm the expression levels. Based on the TCGA database and Oncomine dataset, we found that C1QTNF6 was over expressed in lung adenocarcinoma. The statistical data also showed that the high-regulated C1QTNF6 was related to poor prognosis in patients with lung adenocarcinoma. Moreover, the capabilities of proliferation, migration, and invasion were inhibited owing to the knockdown of C1QTNF6 in lung adenocarcinoma cells. And the phosphorylation of MEK and ERK was blocked by treated si-C1QTNF6 compared with the GAPDH. In conclusion, aberrant C1QTNF6 expression was implicated in terrible prognosis accompanying with the damage of relevant cell potential in lung adenocarcinoma. C1QTNF6 might be an independent predictor of prognosis in lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.